Inflammatory immune response in recipients of transcatheter aortic valves

• DOI: 10.1016/j.xjon.2021.02.012
• Publication Date: 2021-03-14T07:48:16Z
• Authors: Cecilia Veraar; Matthias Koschutnik; Christian Nitsche; Maria Laggner; Dominika Polak; Barbara Bohle; Andreas Mangold; Bernhard Moser; Julia Mascherbauer; Hendrik J. Ankersmit
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Adult: Aortic Valve: Basic Science; 3. Good health

Transcatheter aortic valve implantation (TAVI) is rapidly replacing cardiac surgery due to its minimal invasiveness and practicality. Midterm immunological studies on the biocompatibility of galactose-alpha-1,3-galactose (α-Gal)-carrying bioprosthetic heart valves for TAVI are not available. In this study we investigated whether employed augment an α-Gal-specific antibody-dependent antibody-independent immune response 3 months after implantation.This prospective observational included 27 patients with severe stenosis undergoing 10 mitral regurgitation treated a transcatheter MitraClip (Abbott Laboratories, Abbott Park, Ill) procedure. Blood samples were drawn before 90 days treatment at routine checkup. Serum analyzed using enzyme-linked immunosorbent assay. concentrations immunoglobulin (Ig) G, IgG subclasses IgE, complement factor 3a, NETosis-specific citrullinated H3, systemic inflammation markers soluble suppression tumorigenicity interleukin 33 evaluated.Three TAVI, found significantly increased serum IgG3, H3 levels, (P = .002, P .001, .025, .039, respectively). Sensitization IgE antibodies occurred in 55% all TAVI.Our results indicate that elicits midterm, specific humoral against α-Gal causes unspecific compared implantation. This observation will lead better understanding postintervention morbidity long-term durability bioprostheses indicates caution appropriate when designing strategies younger patients.